Background: Patisiran, an investigational RNA interference therapeutic agent, specifically inhibits hepatic synthesis of transthyretin.
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.
Alnylam Pharmaceuticals, Inc. announced that the Company will present new results for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2023 , October 6-9, 2023.
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the Company has initiated APOLLO-B, a global Phase III placebo-controlled...
Alnylam Pharmaceuticals, Inc., announced that the European Commission (EC) has granted marketing authorization for Onpattro (patisiran) for the treatment of...
Indicated for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy, this is the first RNAi Therapeutic Approved in the European Union (EU).
Alnylam Pharmaceuticals, Inc. announced the submission of its supplemental New Drug Application (sNDA) to the FDA for patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy
Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the FDA has accepted for filing the Company’s supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis
Alnylam Pharmaceuticals, Inc. announced that the FDA has issued a Complete Response Letter (CRL) in response to the Company’s supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis.
Alnylam Pharmaceuticals, Inc. announced positive results from the APOLLO-B Phase III study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.